Gilead Sciences (NASDAQ:GILD) Price Target Raised to $145.00

Gilead Sciences (NASDAQ:GILD) had its target price hoisted by Truist Financial from $140.00 to $145.00 in a report issued on Tuesday morning,Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock.

GILD has been the subject of a number of other research reports. TD Cowen upped their price objective on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Cantor Fitzgerald reissued an “overweight” rating and set a $135.00 price target on shares of Gilead Sciences in a report on Friday, October 31st. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Wall Street Zen cut Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. Finally, Daiwa Capital Markets raised their price target on Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $135.56.

Gilead Sciences Stock Down 0.1%

Gilead Sciences stock opened at $139.55 on Tuesday. The stock has a 50 day moving average of $125.05 and a two-hundred day moving average of $119.38. Gilead Sciences has a twelve month low of $93.37 and a twelve month high of $141.71. The stock has a market capitalization of $173.14 billion, a price-to-earnings ratio of 21.64, a PEG ratio of 0.73 and a beta of 0.33. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same quarter in the previous year, the company posted $2.02 earnings per share. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. As a group, research analysts expect that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the completion of the transaction, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at approximately $76,504,230. The trade was a 16.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the sale, the director directly owned 8,920 shares in the company, valued at $1,115,713.60. This trade represents a 35.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 257,397 shares of company stock worth $33,385,512 over the last ninety days. 0.27% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Gilead Sciences

Several hedge funds have recently added to or reduced their stakes in the business. GoalVest Advisory LLC raised its position in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Corundum Trust Company INC acquired a new position in shares of Gilead Sciences in the third quarter worth $26,000. Harbor Asset Planning Inc. acquired a new position in shares of Gilead Sciences in the second quarter worth $27,000. Financial Consulate Inc. lifted its position in shares of Gilead Sciences by 85.8% in the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 109 shares in the last quarter. Finally, Putney Financial Group LLC boosted its stake in shares of Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Wolfe Research raised its price target to $155 (from $150) and kept an “outperform” rating — implying ~10% upside from current levels. Wolfe Research PT Raise
• Positive Sentiment: Citigroup published a bullish forecast for strong price appreciation, supporting demand expectations for GILD. Citigroup Forecast
• Positive Sentiment: Truist Financial also issued a forecast calling for meaningful upside, lining up with broader analyst optimism. Truist Forecast
• Positive Sentiment: BMO Capital Markets added to the chorus of bullish forecasts, which reinforces analyst-driven buying interest. BMO Forecast
• Positive Sentiment: UBS reiterated expectations for upside, further supporting consensus that GILD’s fundamentals and pipeline justify higher valuations. UBS Note
• Positive Sentiment: Coverage pieces (BarChart, Zacks interest) note that Gilead has outperformed the market and that analysts are broadly optimistic — positive sentiment that can attract momentum flows. BarChart Analysts Overview
• Neutral Sentiment: Zacks flagged increased investor attention to GILD (tracking user searches), which can boost volume but is not a directional catalyst by itself. Zacks Attention Note
• Neutral Sentiment: Reported short-interest data is inconsistent (entries show increases but list 0 shares / NaN), suggesting a data glitch — no clear short-squeeze or heavy shorting signal from this report.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares at ~$139.89 (≈$1.4M), trimming his holding ~1.76%. Insider sales can be read negatively by some investors even if part of routine diversification. SEC Form 4

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.